RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial aims to boost survival for Tough-to-Treat lung cancer
Disease control OngoingThis large study is testing if starting an immunotherapy drug called durvalumab at the same time as standard chemotherapy and radiation is better than the current approach of giving it only after those treatments. It involves 660 adults with stage 3 non-small cell lung cancer tha…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Nanoparticle 'Booster' tested to make radiation hit harder against tough lung cancer
Disease control OngoingThis early-stage study is testing a new nanoparticle drug called NBTXR3 for people with inoperable, recurrent non-small cell lung cancer. The nanoparticle is injected directly into the tumor and is designed to make standard radiation therapy more powerful at killing cancer cells,…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug duo targets Tough-to-Treat lung cancer mutation
Disease control OngoingThis study is testing whether combining two drugs, trametinib and docetaxel, can help control advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation. It is for patients whose cancer has continued to grow despite one or two prior treatments. …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New drug duo tested in fight against tough lung cancers
Disease control OngoingThis early-stage trial is testing a combination of two oral drugs, sapanisertib and telaglenastat, in patients with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. The main goals are to find the safest and most effective dose and…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Scientists test Four-Drug cocktail in fight against tough lung cancer
Disease control OngoingThis early-stage study is testing a combination of four drugs for people with a specific type of advanced lung cancer (ALK-positive). The main goals are to find the safest dose of the new drug, ensartinib, when given with three other cancer drugs, and to see if this combination h…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New Two-Drug attack on tough lung cancer
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sapanisertib and osimertinib, for people with advanced non-small cell lung cancer. The cancer must have a specific genetic change (EGFR mutation) and has gotten worse after treatment with a standard targeted drug. …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Scientists test vitamin a boost to help immune system fight advanced lung cancer
Disease control OngoingThis early-stage study is testing a new combination treatment for advanced non-small cell lung cancer that has spread or returned. Researchers are combining a drug made from vitamin A (ATRA) with an immunotherapy drug (atezolizumab) to see if it is safe and to find the best dose.…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
One-Two punch for lung cancer: can zapping tumors boost drug power?
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug duo tested for Tough-to-Treat lung cancer
Disease control OngoingThis early-stage trial is testing the safety and best dose of a two-drug combination for people with a specific type of advanced lung cancer. The study is for adults whose EGFR-mutant non-small cell lung cancer has continued to grow despite prior targeted therapy. Researchers wan…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New combo attack on tough lung cancer
Disease control OngoingThis early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for Tough-to-Treat lung cancer: testing a powerful drug duo
Disease control OngoingThis study is testing whether combining two drugs, atezolizumab and cobimetinib, can help control advanced non-small cell lung cancer that has spread or returned and has stopped responding to a common type of immunotherapy. The trial aims to see if this combination can shrink tum…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test supercharged cord blood cells as new weapon against tough lung cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy for people with advanced non-small cell lung cancer that has spread and no longer responds to standard immunotherapy. Researchers are giving patients specially modified immune cells (called NK cells) taken from umbilica…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets genetic driver in advanced lung cancer
Disease control OngoingThis study is testing an oral drug called selpercatinib for people with advanced non-small cell lung cancer that has a specific genetic change called a RET fusion. The goal is to see how well the drug shrinks tumors and controls the cancer by blocking the abnormal protein driving…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Can a One-Two punch of radiation and immune therapy better fight lung cancer?
Disease control OngoingThis study is testing if combining a targeted, high-dose radiation treatment with an immunotherapy drug works better than radiation alone for certain early-stage or recurrent non-small cell lung cancers. About 140 participants will be randomly assigned to receive either the radia…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New combo attack on tough lung cancers
Disease control OngoingThis study is testing a combination of two drugs, trametinib and pembrolizumab, for people with advanced non-small cell lung cancer that has come back or spread after previous treatments. The goal is to see if the drugs work better together to control the cancer and to find the s…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Scientists aim to zap lung tumors more precisely, spare healthy tissue
Disease control OngoingThis study is testing two advanced, precise ways to deliver radiation therapy alongside standard chemotherapy for people with stage II or III non-small cell lung cancer. The goal is to see if these methods can safely deliver a stronger dose of radiation directly to the tumor whil…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug duo tested for Tough-to-Treat lung cancer
Disease control OngoingThis early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
New drug duo tested to halt lung Cancer's spread
Disease control OngoingThis study tested whether combining two targeted drugs works better than either drug alone to control advanced non-small cell lung cancer that has worsened after initial chemotherapy. It involved 125 patients whose tumors lack a specific genetic marker (EGFR mutation). The goal w…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Can blood tests help tame Chemo's painful side effects?
Knowledge-focused TerminatedThis study aims to see if doctors can reliably measure the amount of a common chemotherapy drug, paclitaxel, in a patient's blood. The goal is to learn if tracking these drug levels can help doctors adjust doses to better fight cancer while reducing a major side effect: nerve dam…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC